Epifanio Fichera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Epifanio Fichera has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Reinhard Glueck
Etna Biotech S.R.L, via Vincenzo Lancia, 57—Zona Industriale Blocco Palma 1, Catania, Italy
2 shared publications- Yoko Fujita-Yamaguchi
Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA
2 shared publications Alessandro Lombardo
Parco Scientifico E Tecnologico Della Sicilia, via Vincenzo Lancia, 57 - Zona Industriale Blocco Palma 1
1 shared publicationAlessandro Pedretti
Department of Pharmaceutical Sciences, University of Milan, Milan, Italy
1 shared publication- Anabela Cordeiro-Da-Silva
Host-Parasite Interactions, I3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal
1 shared publication - Begoña Pérez-Cabezas
CAGE, Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal
1 shared publication
Latest Publications
- Open Access
- 27 November 2017
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 11 (11) , e0005951
Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis
The notion that previous infection by Leishmania spp. in endemic areas leads to robust anti-Leishmania immunity, supports vaccination as a potentially effective approach to prevent disease development. Nevertheless, to date there is no vaccine available for human leishmaniasis. We optimized and assessed in vivo the safety and immunogenicity of an innovative vaccine candidate against human visceral leishmaniasis (VL), consisting of Virus-Like Particles (VLP) loaded with three different recombinant proteins (LJL143 from Lutzomyia longipalpis saliva as the vector-derived (VD) component, and KMP11 and LeishF3+, as parasite-derived (PD) antigens) and adjuvanted with GLA-SE, a TLR4 agonist. No apparent adverse reactions were observed during the experimental time-frame, which together with the normal hematological parameters detected seems to point to the safety of the formulation. Furthermore, measurements of antigen-specific cellular and humoral responses, generally higher in immunized versus control groups, confirmed the immunogenicity of the vaccine formulation. Interestingly, the immune responses against the VD protein were reproducibly more robust than those elicited against leishmanial antigens, and were apparently not caused by immunodominance of the VD antigen. Remarkably, priming with the VD protein alone and boosting with the complete vaccine candidate contributed towards an increase of the immune responses to the PD antigens, assessed in the form of increased ex vivo CD4+ and CD8+ T cell proliferation against both the PD antigens and total Leishmania antigen (TLA). Overall, our immunogenicity data indicate that this innovative vaccine formulation represents a promising anti-Leishmania vaccine whose efficacy deserves to be tested in the context of the “natural infection”. Although vaccination is accepted as a potentially effective approach to prevent leishmaniasis, to date there is no vaccine available for human disease. The research on the topic is therefore extremely important, and the design and testing of new vaccine approaches, as well as non-traditional immunization schemes continues to be as relevant as before. This study proposes an innovative vaccine approach for human visceral leishmaniasis, not only due to its multi-antigen nature which contemplates both parasite and vector derived proteins, but also because it explores the possibility of the use of Influenza virosomes as antigen-delivery vehicles. A strong TLR-4 agonist completes the vaccine formulation. Here we show the rationale-behind this vaccine approach, the safety of all the vaccine components in our in vivo context, and immunogenicity studies of the optimized vaccine candidate in mice that explored the contribution of the virosome to the antigen-elicited immune responses. Additionally, we tested an unusual immunization scheme that potentiated the final vaccine-elicited immune responses. This prime-boost immunization approach gives relevance to the use of both parasite and vector derived antigens together as an anti-Leishmania vaccine, and proposes a new strategy for vaccination in endemic areas, where people are constantly exposed to sand fly bites.
- 27 November 2017
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 11 (11) , e0005951
Open AccessPre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis
The notion that previous infection by Leishmania spp. in endemic areas leads to robust anti-Leishmania immunity, supports vaccination as a potentially effective approach to prevent disease development. Nevertheless, to date there is no vaccine available for human leishmaniasis. We optimized and assessed in vivo the safety and immunogenicity of an innovative vaccine candidate against human visceral leishmaniasis (VL), consisting of Virus-Like Particles (VLP) loaded with three different recombinant proteins (LJL143 from Lutzomyia longipalpis saliva as the vector-derived (VD) component, and KMP11 and LeishF3+, as parasite-derived (PD) antigens) and adjuvanted with GLA-SE, a TLR4 agonist. No apparent adverse reactions were observed during the experimental time-frame, which together with the normal hematological parameters detected seems to point to the safety of the formulation. Furthermore, measurements of antigen-specific cellular and humoral responses, generally higher in immunized versus control groups, confirmed the immunogenicity of the vaccine formulation. Interestingly, the immune responses against the VD protein were reproducibly more robust than those elicited against leishmanial antigens, and were apparently not caused by immunodominance of the VD antigen. Remarkably, priming with the VD protein alone and boosting with the complete vaccine candidate contributed towards an increase of the immune responses to the PD antigens, assessed in the form of increased ex vivo CD4+ and CD8+ T cell proliferation against both the PD antigens and total Leishmania antigen (TLA). Overall, our immunogenicity data indicate that this innovative vaccine formulation represents a promising anti-Leishmania vaccine whose efficacy deserves to be tested in the context of the “natural infection”. Although vaccination is accepted as a potentially effective approach to prevent leishmaniasis, to date there is no vaccine available for human disease. The research on the topic is therefore extremely important, and the design and testing of new vaccine approaches, as well as non-traditional immunization schemes continues to be as relevant as before. This study proposes an innovative vaccine approach for human visceral leishmaniasis, not only due to its multi-antigen nature which contemplates both parasite and vector derived proteins, but also because it explores the possibility of the use of Influenza virosomes as antigen-delivery vehicles. A strong TLR-4 agonist completes the vaccine formulation. Here we show the rationale-behind this vaccine approach, the safety of all the vaccine components in our in vivo context, and immunogenicity studies of the optimized vaccine candidate in mice that explored the contribution of the virosome to the antigen-elicited immune responses. Additionally, we tested an unusual immunization scheme that potentiated the final vaccine-elicited immune responses. This prime-boost immunization approach gives relevance to the use of both parasite and vector derived antigens together as an anti-Leishmania vaccine, and proposes a new strategy for vaccination in endemic areas, where people are constantly exposed to sand fly bites.
- 9 May 2016
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 32 (17) , 2672-2680
A computational model to predict the immune system activation by citrus-derived vaccine adjuvants
Motivation: Vaccines represent the most effective and cost-efficient weapons against a wide range of diseases. Nowadays new generation vaccines based on sub-unit antigens reduce adverse effects in high risk individuals. However, vaccine antigens are often poor immunogens when administered alone. Adjuvants represent a good strategy to overcome such hurdles, indeed they are able to: enhance the immune response; allow antigens sparing; accelerate the specific immune response; and increase vaccine efficacy in vulnerable groups such as newborns, elderly or immuno-compromised people. However, due to safety concerns and adverse reactions, there are only a few adjuvants approved for use in humans. Moreover, in practice current adjuvants sometimes fail to confer adequate stimulation. Hence, there is an imperative need to develop novel adjuvants that overcome the limitations of the currently available licensed adjuvants.
- 9 May 2016
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 32 (17) , 2672-2680
A computational model to predict the immune system activation by citrus-derived vaccine adjuvants
Motivation: Vaccines represent the most effective and cost-efficient weapons against a wide range of diseases. Nowadays new generation vaccines based on sub-unit antigens reduce adverse effects in high risk individuals. However, vaccine antigens are often poor immunogens when administered alone. Adjuvants represent a good strategy to overcome such hurdles, indeed they are able to: enhance the immune response; allow antigens sparing; accelerate the specific immune response; and increase vaccine efficacy in vulnerable groups such as newborns, elderly or immuno-compromised people. However, due to safety concerns and adverse reactions, there are only a few adjuvants approved for use in humans. Moreover, in practice current adjuvants sometimes fail to confer adequate stimulation. Hence, there is an imperative need to develop novel adjuvants that overcome the limitations of the currently available licensed adjuvants.
- 1 January 2009
- Published by Springer Nature
- Vol. 655, 243-252
New Strategies to Overcome the Drawbacks of Currently Available Flu Vaccines
Vaccination represents the most efficient tool to control morbidity and mortality resulting from influenza infections in humans. The currently licensed influenza vaccines provide good protection levels in healthy adults, whereas lower protection is generally achieved in ageing individuals who are at a higher risk of developing severe clinical manifestations. Future improvements in influenza vaccines should address the needs of high risk groups including the elderly, small children and chronic patients. Recently, due to the increased incidence of avian influenza pandemic outbreaks, the prevention of a potential human influenza pandemic turned into another crucial issue in the influenza vaccination field. The development and validation of manufacturing processes for efficient and safe pandemic vaccines became one of the top priorities of health, regulatory and funding agencies all over the world. In the pandemic context, the development of novel vaccines administered via the mucosal route may play a significant role by reducing virus shedding from infected individuals. This chapter provides insights in the limitations of existing manufacturing processes, new approaches to overcome limitation in vaccine production, mechanisms of action of current vaccines and discuss potential strategies to improve the immunogenicity and efficacy of influenza vaccines.
- 1 January 2009
- Published by Springer Nature
- Vol. 655, 243-252
New Strategies to Overcome the Drawbacks of Currently Available Flu Vaccines
Vaccination represents the most efficient tool to control morbidity and mortality resulting from influenza infections in humans. The currently licensed influenza vaccines provide good protection levels in healthy adults, whereas lower protection is generally achieved in ageing individuals who are at a higher risk of developing severe clinical manifestations. Future improvements in influenza vaccines should address the needs of high risk groups including the elderly, small children and chronic patients. Recently, due to the increased incidence of avian influenza pandemic outbreaks, the prevention of a potential human influenza pandemic turned into another crucial issue in the influenza vaccination field. The development and validation of manufacturing processes for efficient and safe pandemic vaccines became one of the top priorities of health, regulatory and funding agencies all over the world. In the pandemic context, the development of novel vaccines administered via the mucosal route may play a significant role by reducing virus shedding from infected individuals. This chapter provides insights in the limitations of existing manufacturing processes, new approaches to overcome limitation in vaccine production, mechanisms of action of current vaccines and discuss potential strategies to improve the immunogenicity and efficacy of influenza vaccines.
- 24 February 2000
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 268 (3) , 886-892
Promoter Usage for Insulin-like Growth Factor-II in Cancerous and Benign Human Breast, Prostate, and Bladder Tissues, and Confirmation of a 10th Exon
- 24 February 2000
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 268 (3) , 886-892
Promoter Usage for Insulin-like Growth Factor-II in Cancerous and Benign Human Breast, Prostate, and Bladder Tissues, and Confirmation of a 10th Exon